TP53 and acute myeloid leukemia: Interestingly, although TP53 mutations are typically found in only ~ 10% of AML patients, after treatment with currently available therapeutics their frequency increases by approximately 5-fold; this is a clinical outcome known as treatment-related AML or t-AML.